In addition, studies have shown that the diagnostic specificity of MMP-3 for patients with early-RA is not high enough, but serum MMP-3 can still be used as an effective indicator to evaluate the difference in the prognosis of joint destruction in patients with RA, reflecting the disease activity and treatment response of patients with moderate to severe RA.[8] Methotrexate (MTX) is commonly used to treat RA in clinical practice. This evidence concerns the gene MMP3 and rheumatoid arthritis.